Considering Personalized Interferon Beta Therapy for COVID-19

Antimicrob Agents Chemother. 2021 Mar 18;65(4):e00065-21. doi: 10.1128/AAC.00065-21. Print 2021 Mar 18.
No abstract available

Keywords: COVID-19; biotherapy; interferon beta.

Publication types

  • Letter
  • Comment

MeSH terms

  • COVID-19*
  • Humans
  • Interferon beta-1a
  • Lopinavir
  • Ritonavir
  • SARS-CoV-2

Substances

  • Lopinavir
  • Ritonavir
  • Interferon beta-1a